Table of Contents
Brain Sci., Volume 9, Issue 5 (May 2019) – 29 articles
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by a wide range of [...] Read more. Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by a wide range of intellectual ability, autism and to various degrees of behavior and social difficulties. Over the past decades, significant advancements have been made in characterizing the molecular and cellular underpinnings of FXS, leading to a better diagnosis. Further, extensive research and preclinical studies have been conducted to develop molecular signatures for target drug development and pharmacologic treatments. However, the lack of feasible biomarkers limits our ability to monitor disease severity and to evaluate the clinical benefit of pharmaceutical interventions. This review highlights the efforts made in establishing potential molecular biomarkers in FXS by using in vivo and in vitro models and the promising stories of the ones that have proven their worth in current human clinical trials. View this paper